Abstract
The growing demand for new drugs faces important barriers to be overcome. Such barriers are related to efficacy, safety, compliance with regulatory requirements and cost-effectiveness balance. Despite the progressive investment of companies in research, studies show that in the United States, only 0.1% of new drugs under development advance to clinical studies. Within these, only 10.0% ar…